MetaCap

Hyperfine Inc. Class A (HYPR)

NASDAQ: HYPRHealth CareBiotechnology: Electromedical & Electrotherapeutic ApparatusUSD

0.5465+0.0224 (+4.27%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

HYPR stock chart

Technical analysis

Key statistics

All statistics
Market cap
$57.96M
EPS (TTM)
-$0.29
52-week range
0.488 – 1.94
Day range
0.4881 – 0.55
Volume / Avg
1.24M / 760.76K
Beta
—

52-week range

$0.488$1.94

HYPR stock today

On Nov 20, HYPR ended the session at $0.5465, adding $0.0224 (4.27%), versus the S&P 500's 3.70% decline. Shares are 71.8% below their 52-week high of $1.94, set on May 1, 2026 and 12.0% above the 52-week low of $0.488, near the bottom of the past year's range. HYPR is down 44.2% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 48.0%.

Hyperfine has posted a net loss over the last twelve months (EPS of -$0.29), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About Hyperfine

Company profile

Hyperfine, Inc., a health technology company, engages in the production, supply, service, and commercialization of magnetic resonance imaging (MRI) products. Its Swoop Portable MR Imaging System produces images at a lower magnetic field strength than conventional MRI scanners. The company also offers support and technical assistance services, as well as Hyperfine Image Viewer, a cloud picture archiving and communication system.

Industry
Biotechnology: Electromedical & Electrotherapeutic Apparatus
CEO
Ms. Maria Degois-Sainz
Headquarters
Guilford, CT
Employees
102
IPO year
2021

Financial highlights

Full financials

In fiscal 2025, Hyperfine generated $13.6 million in revenue, up 5.2% from fiscal 2024, its 5th consecutive year of revenue growth. Hyperfine reported a net loss of $35.6 million, compared with a loss of $40.7 million a year earlier. Gross margin was 49.8% (up from 45.7%) and operating margin -273.4%.

Hyperfine annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue$13.56M$12.89M$11.03M$6.81M$1.50M
Growth+5.22%+16.84%+61.90%+355.48%+408.84%
Net income$-35.57M$-40.72M$-44.24M$-44.24M$-64.85M
EPS (diluted)$-0.43$-0.56$-0.62$-1.04$-17.57

Analyst forecast

Forecast

Consensus (3 analysts)

none

Avg. price target

$2.03+271.45%

  • Strong buy 0
  • Buy 3
  • Hold 0
  • Sell 0
  • Strong sell 0

Target range

Low $1.60High $2.50

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 9, 2026
EPS actual vs est.
$-0.06 vs $-0.08
Surprise
+25.00%

HYPR news

All HYPR news

Hyperfine peers

Health Care sector
HYPR peer companies
CompanyPrice% ChgMarket capCompare
NRXSNeuraxis Inc.4.22-6.22%$59.90Mvs HYPR
OMOutset Medical Inc.2.81-3.44%$53.03Mvs HYPR
POCIPrecision Optics Corporation Inc.4.12+1.41%$45.30Mvs HYPR
ECORelectroCore Inc.4.42-8.87%$40.78Mvs HYPR
QTIQT Imaging Holdings Inc.1.92+2.67%$28.21Mvs HYPR
HSDTSolana Company Class A1.49-10.24%$93.70Mvs HYPR
STXSStereotaxis Inc.0.9422-6.71%$95.03Mvs HYPR
VANIVivani Medical Inc.1.14+4.59%$102.83Mvs HYPR

Indexes, lists and sector

Hyperfine stock FAQ

What is Hyperfine's stock price today?

HYPR last traded at $0.5465 as of Nov 20, 4:00 PM EST, up 4.27% on the day. Prices are delayed at least 15 minutes.

Who is Hyperfine's CEO?

Ms. Maria Degois-Sainz is the chief executive officer of Hyperfine Inc. Class A, which has about 102 employees.

What is the HYPR 52-week high?

The 52-week high for HYPR is $1.94 and the 52-week low is $0.488. The stock is currently 71.8% below its high.

Compare HYPR